Published in Biotech Law Weekly, October 14th, 2005
This milestone now allows users of this new radioactive source to be reimbursed by Medicare and Medicaid for the treatment of their patients.
With this payment code in place, along with the U.S. Food and Drug Administration (FDA) 510(k) premarket clearance received earlier this year, the company has no more Government regulatory barriers to commercialization. The company currently plans to treat a select number of patients in the last quarter of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.